{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:11:22Z","timestamp":1792681882640,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/objectives: Infections caused by carbapenem-resistant Enterobacterales (CRE) are progressively increasing in Pediatric Intensive Care Units (PICUs). Its treatment is challenging due to the lack of pediatric trials. CRE infections are associated with significantly poor outcomes, but ceftazidime\u2013avibactam (CAZ-AVI) has been reported to be successful in their treatment. This study aimed to describe the use and outcome of CAZ-AVI in a PICU. Results: Ten patients were included, with 12 episodes of clinical suspicion or confirmed multidrug-resistant (MDR) bacterial infections treated with CAZ-AVI for surgical prophylaxis, suspicion of sepsis, pneumonia, and surgical wound infection. Of these patients, 80% received empirical treatment because of previous MDR bacterial colonization, and 60% were administrated combination therapy with aztreonam for Metallo-\u03b2-Lactamases (MBL)strains. No bacteria were resistant to CAZ-AVI. The average duration of the treatment was 3 days when cultures turned negative and 7 days when MDR bacteria were isolated. Methods: This was an observational prospective study of children treated with CAZ-AVI in the PICU of a tertiary hospital in 2022. Epidemiological, clinical, microbiological, and outcome data were collected. Conclusions: The most frequent use of CAZ-AVI in our PICU was the short-term empirical treatment for patients with previous MDR bacterial colonization and clinical suspicion of bacteremia or sepsis. Furthermore, the combination of CAZ-AVI plus aztreonam could be more effective for CRE infections, especially type Ambler class B as MBL strains.<\/jats:p>","DOI":"10.3390\/antibiotics13111037","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:57:34Z","timestamp":1730692654000},"page":"1037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Use of Ceftazidime\u2013Avibactam in a Pediatric Intensive Care Unit\u2014An Observational Prospective Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-586X","authenticated-orcid":false,"given":"Raquel","family":"Garc\u00eda Romero","sequence":"first","affiliation":[{"name":"Pediatrics Department, Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6898-2109","authenticated-orcid":false,"given":"Elena","family":"Fres\u00e1n-Ruiz","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Barcelona, Spain"},{"name":"Immunological and Respiratory Disorders in the Pediatric Critical Patient Research Group, Institut de Recerca Sant Joan de D\u00e9u, University of Barcelona, Hospital Sant Joan de D\u00e9u, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-5939","authenticated-orcid":false,"given":"Carmina","family":"Guitart","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Barcelona, Spain"},{"name":"Immunological and Respiratory Disorders in the Pediatric Critical Patient Research Group, Institut de Recerca Sant Joan de D\u00e9u, University of Barcelona, Hospital Sant Joan de D\u00e9u, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-2995","authenticated-orcid":false,"given":"Sara","family":"Bobillo-Perez","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Barcelona, Spain"},{"name":"Immunological and Respiratory Disorders in the Pediatric Critical Patient Research Group, Institut de Recerca Sant Joan de D\u00e9u, University of Barcelona, Hospital Sant Joan de D\u00e9u, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Jordan","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Hospital Sant Joan de D\u00e9u, University of Barcelona, 08950 Barcelona, Spain"},{"name":"Consorcio de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5001\/omj.2019.37","article-title":"WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain","volume":"34","author":"Asokan","year":"2019","journal-title":"Oman Med. J."},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2019). Antibiotic Resistance Threats in the United States, 2019."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofy222","DOI":"10.1093\/ofid\/ofy222","article-title":"Increased 30-Day Mortality Associated with Carbapenem-Resistant enterobacteriaceae in Children","volume":"5","author":"Chiotos","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0038-1677535","article-title":"Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance","volume":"8","author":"Folgori","year":"2019","journal-title":"J. Pediatr. Intensive Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.35366\/92381","article-title":"Documento de Posicionamiento de La Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda-Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica Sobre El Tratamiento de Las Infecciones Por Bacterias Multirresistentes","volume":"33","author":"Ramos","year":"2020","journal-title":"Rev. Latinoam. De Infectolog\u00eda Pedi\u00e1trica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3201\/eid2111.150548","article-title":"Carbapenem-resistant Enterobacteriaceae in children, United States, 1999\u20132012","volume":"21","author":"Logan","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jpids\/piz085","article-title":"Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children","volume":"9","author":"Chiotos","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/AAC.01440-17","article-title":"Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children","volume":"61","author":"Chiotos","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/INF.0000000000000471","article-title":"Pediatric Carbapenem-Resistant Enterobacteriaceae in Los Angeles, California, a High-Prevalence Region in the United States","volume":"34","author":"Pannaraj","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jinf.2015.10.008","article-title":"Comprehensive Clinical and Epidemiological Assessment of Colonisation and Infection due to Carbapenemase-Producing Enterobacteriaceae in Spain","volume":"72","author":"Oteo","year":"2016","journal-title":"J. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit. Care"},{"key":"ref_13","unstructured":"US Food and Drug Administration (2019, October 03). Ceftazidime-Avibactam Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and Efficacy of Ceftazidime\u2013Avibactam in the Treatment of Children \u22653 Months to <18 Years with Complicated Urinary Tract Infection","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and Efficacy of Ceftazidime-Avibactam plus Metronidazole in the Treatment of Children \u22653 Months to <18 Years with Complicated Intra-Abdominal Infection","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_17","first-page":"e02603","article-title":"Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: A Systematic Review and Meta-Analysis","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase\u2013Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2147\/IDR.S209264","article-title":"Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime\/Avibactam","volume":"13","author":"Bassetti","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients with Infections Caused by Klebsiella Pneumoniae Carbapenemase-Producing K. Pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.2147\/IDR.S369368","article-title":"Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales","volume":"15","author":"Wang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt.2460","article-title":"Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older","volume":"111","author":"Franzese","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e02105","DOI":"10.1128\/AAC.02105-19","article-title":"Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam","volume":"64","author":"Li","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment across Adult Indications and Patient Subgroups","volume":"12","author":"Li","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofw090","DOI":"10.1093\/ofid\/ofw090","article-title":"Metallo-\u03b2-Lactamase (MBL)-Producing Enterobacteriaceaein United States Children: Table 1","volume":"3","author":"Logan","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mauri, C., Maraolo, A.E., Di Bella, S., Luzzaro, F., and Principe, L. (2021). The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing Gram-negatives: A systematic review of in vitro studies and clinical cases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081012"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.09.014","article-title":"Molecular Diversity in Mechanisms of Carbapenem Resistance in Paediatric Enterobacteriaceae","volume":"39","author":"Little","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jajoo, M., Manchanda, V., Chaurasia, S., Sankar, M.J., Gautam, H., Agarwal, R., Yadav, C.P., Aggarwal, K.C., Chellani, H., and Ramji, S. (2018). Alarming Rates of Antimicrobial Resistance and Fungal Sepsis in Outborn Neonates in North India. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0180705"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhin.2017.05.025","article-title":"Risk Factors and Clinical Outcomes for Carbapenem-Resistant Gram-Negative Late-Onset Sepsis in a Neonatal Intensive Care Unit","volume":"97","author":"Nour","year":"2017","journal-title":"J. Hosp. Infect."},{"key":"ref_31","first-page":"60","article-title":"Evolution of the Incidence of Colonized and Infected Patients by VIM Carbapenemase-Producing Bacteria in a Pediatric Hospital in Spain","volume":"32","author":"Gallego","year":"2019","journal-title":"PubMed"},{"key":"ref_32","first-page":"10","article-title":"Emergence of Ceftazidime-Avibactam Resistance due to Plasmid-Borne BlaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fiore, M., Alfieri, A., Di Franco, S., Pace, M.C., Simeon, V., Ingoglia, G., and Cortegiani, A. (2020). Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics, 9.","DOI":"10.3390\/antibiotics9070388"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/ofid\/ofw172.1568","article-title":"In Vitro Synergy of Ceftazidime-Avibactam plus Rifampin against Pseudomonas Aeruginosa","volume":"3","author":"Sibley","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas Aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","first-page":"460","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Doi","year":"2016","journal-title":"Virulence"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy to Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae and Pseudomonas Aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00634","DOI":"10.1016\/j.idcr.2019.e00634","article-title":"Successful Treatment of KPC-MDR Septic Shock with Ceftazidime-Avibactam in a Pediatric Critically Ill Patient","volume":"18","author":"Vargas","year":"2019","journal-title":"IDCases"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e02243-16","DOI":"10.1128\/AAC.02243-16","article-title":"Can Ceftazidime-Avibactam and Aztreonam Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijmmb.2021.12.006","article-title":"Susceptibility testing for aztreonam plus ceftazidime\/avibactam combination: A general guidance for clinical microbiology laboratories in India","volume":"40","author":"Bakthavatchalam","year":"2022","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_42","unstructured":"Europa.Eu (2024, September 10). Retrieved. 20 October 2024. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240422162367\/anx_162367_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","article-title":"Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children","volume":"21","author":"Weiss","year":"2020","journal-title":"Pediatr. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00003246-199206000-00002","article-title":"Definitions for sepsis and organ failure","volume":"20","author":"Bone","year":"1992","journal-title":"Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2011-200598","article-title":"British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Children: Update 2011","volume":"66","author":"Harris","year":"2011","journal-title":"Thorax"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.earlhumdev.2013.07.023","article-title":"Community-acquired pneumonia in children","volume":"89","author":"Cardinale","year":"2013","journal-title":"Early Hum. Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/INF.0b013e318255dc5b","article-title":"Antibiotic Therapy for Pediatric Community-acquired Pneumonia","volume":"35","author":"Esposito","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The Management of Community-Acquired Pneumonia in Infants and Children Older than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","unstructured":"US Department of Health and Human Services Food and Drug Administration, and Center for Drug Evaluation and Research (CDER) Guidance for Industry (2024, February 15). Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs."},{"key":"ref_51","unstructured":"(2023, January 03). TC for DC and P. Pneumonia (Ventilator-Associated [VAP] and Non-Ventilator-Associated Pneumonia [PNEU]). Event, Available online: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/6pscvapcurrent.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamasurg.2017.0904","article-title":"Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017","volume":"152","author":"Umscheid","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.37201\/req\/s03.18.2022","article-title":"New definitions of susceptibility categories EUCAST 2019: Clinic application","volume":"35","author":"Robles","year":"2022","journal-title":"Rev. Esp. Quimioter."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:37Z","timestamp":1760113657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["antibiotics13111037"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13111037","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]}}}